Across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — the chronic kidney disease market size was valued at approximately USD 5 billion in 2025 and is projected to keep expanding through 2036. Today's landscape is built on erythropoietin stimulating agents, ACE inhibitors, ARBs, antidiabetic drugs, secondary hyperparathyroidism treatments, and urate-lowering therapies, with SGLT2 inhibitors and non-steroidal MRAs now emerging as the dominant growth segments within the broader kidney disease market.

Chronic Kidney Disease Epidemiology

Patient burden data underpin every forecast in this space. In 2025, the 7MM housed roughly 82.5 million people living with the disease, of whom nearly 14.5 million had received a formal diagnosis. The US carried the single largest diagnosed population, at around 3.8 million cases, or roughly a quarter of the 7MM total. Stage III was the most common severity level among US patients, and hyperparathyroidism was the leading complication, ahead of anemia and metabolic acidosis. Diagnosed cases also skewed toward women, and continued growth in the geriatric population, combined with wider eGFR and albuminuria screening, is expected to keep pushing the chronic kidney disease epidemiology forecast upward through 2036.

Current Chronic Kidney Disease Treatment Landscape

Care generally follows a stepwise, additive model. RAS blockade and lifestyle intervention come first, followed by SGLT2 inhibitors such as empagliflozin (JARDIANCE) and dapagliflozin (FARXIGA/FORXIGA), which now serve as background therapy across most disease types. Where diabetes-related disease and residual albuminuria persist, the non-steroidal MRA finerenone (KERENDIA) is frequently added to further lower cardiorenal risk. This layering of therapies rather than reliance on a single agent is what continues to reshape the chronic renal failure market.

Key Factors Driving the Chronic Kidney Disease Market

Growth is being driven by three main forces. Expanded screening among diabetic, hypertensive, and cardiovascular patients is identifying more cases earlier, feeding a larger treated population. At the same time, combination cardiorenal regimens — pairing SGLT2 inhibitors with non-steroidal MRAs and, increasingly, aldosterone synthase inhibitors — are becoming the standard rather than the exception, and this shift is considered the single biggest revenue contributor in the space. A broadening late-stage pipeline covering endothelin receptor antagonism, aldosterone synthase inhibition, APOL1 inhibition, and cell-based therapy is adding further competitive depth to the CKD market.

Chronic Kidney Disease Drug Analysis & Competitive Landscape

Several late-stage assets illustrate where the next wave of growth may come from. AstraZeneca's zibotentan/dapagliflozin combination progressed into Phase III proteinuria trials after strong Phase IIb results. Boehringer Ingelheim's vicadrostat-plus-empagliflozin regimen has already demonstrated notable albuminuria reduction in earlier testing. ProKidney's cell therapy candidate rilparencel and Mineralys Therapeutics' lorundrostat remain in active late-stage development, while Maze Therapeutics' MZE829 recently delivered the first clinical proof-of-concept in APOL1-mediated kidney disease — developments that are steadily diversifying the chronic kidney disease drugs market beyond its traditional glycemic- and blood-pressure-centered approach.

Chronic Kidney Disease Unmet Needs

Even with this progress, meaningful gaps remain. Existing treatments slow disease progression but do not halt or reverse it, and because early-stage disease tends to be silent, many patients are only diagnosed once considerable kidney damage has already occurred. Cardiorenal risk also persists even under combination SGLT2 inhibitor and MRA therapy, and precision options for genetically driven forms of disease, such as APOL1-mediated kidney disease, remain limited — a gap that continues to define opportunity within the renal failure treatment market.

Chronic Kidney Disease Market Outlook

Looking forward, SGLT2 inhibitors and finerenone are expected to remain the volume backbone of therapy, while endothelin- and aldosterone-pathway combinations are set to drive the next phase of add-on growth, contingent on outcomes and safety data around fluid retention and hyperkalemia. Rilparencel and MZE829 could achieve premium positioning in advanced and genetically defined disease if pivotal trials succeed, and anemia-targeted candidates such as DISC-0974 may open a largely uncontested new revenue segment. Regionally, the US holds the largest share, followed by Germany and the UK in Europe, while Japan contributes a sizeable double-digit portion of the 7MM total. As diagnosis rates climb and the late-stage pipeline matures, adjacent segments — including the chronic kidney disease treatment market and the end stage renal disease market — are also poised to expand through 2036.

Latest Reports Offered by Delveinsight

growth hormone deficiency market | menopause market | molecular glue market | vaginal and vulval inflammatory diseases market | adalimumab biosimilar | alopecia market | biliary stents market | cancer vaccines market | car t cell therapy market | chronic cutaneous ulcer market | chronic kidney disease market | congenital heart defect devices market | dental laser market | neurovascular devices market | pancreatic cancer market | radial artery compression device market | amyotrophic lateral sclerosis market | atrial fibrillation market | automated suturing devices market | brain monitoring devices market | cardiovascular monitoring and diagnostic devices market | cervix lesion market | chronic pain market | coronary stents market | dry age-related macular degeneration market | fatty acid oxidation disorders market | 

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com